New Delhi, April 4 (IANS) India’s drug regulators are stepping up oversight of fast-growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.The move comes as the Indian Pharmacopoeia Commission (IPC), which functions under the Ministry of Health, has been tasked with systematically collecting and analysing adverse event reports linked to these drugs.The initiative aims to…
Latest GLP-1 Receptor Agonists News & Updates
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.The companies, namely Sun Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories, launched their variants a day after Hyderabad-based Natco Pharma launched its generic semaglutide injection in India, priced at Rs 1,290 per month.Sun Pharma launched semaglutide…